Long-acting injectable Cabotegravir: How drug concentrations could help guide patient management

Br J Clin Pharmacol. 2022 Oct;88(10):4384-4386. doi: 10.1111/bcp.15410. Epub 2022 Aug 16.

Authors

Jose R Castillo-Mancilla¹, Peter L Anderson²

Affiliations

¹ Division of Infectious Diseases, School of Medicine, University of Colorado-AMC, Aurora, CO, USA.
² Colorado Antiviral Pharmacology Laboratory and Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, CO, USA.

PMID: 35971819
DOI: 10.1111/bcp.15410

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Anti-HIV Agents* / therapeutic use
Diketopiperazines
HIV Infections* / drug therapy
Humans
Pyridones / therapeutic use

Substances

Anti-HIV Agents
Diketopiperazines
Pyridones
cabotegravir

Grants and funding

R01 AI145453/AI/NIAID NIH HHS/United States